Status: Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).
Participants needed: 284
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAUpdated: Aug 6, 2026Locations: 51
Eligibility criteria
Males are eligible to participate if they agree to use contraception as describe... [+7]
A diagnosis of COPD or a primary diagnosis of asthma, as judged by the investiga... [+27]